Ken Nordeen

Ken Nordeen has several years of experience in the pharmaceutical industry, primarily focused on drug safety and pharmacovigilance. Ken started their career as a Consultant at Ranbaxy in 2008 and has since worked at various companies in similar roles.

At Oscient Pharmaceuticals Corp., Nordeen served as a Project Manager and Business Configuration Subject Matter Expert (SME) for the procurement and implementation of a new drug safety reporting system. Ken also analyzed the capabilities of different applications and coordinated the vendor selection process.

Nordeen then worked as a Consultant at Pfizer from 2007 to 2008, where they likely provided expertise in the drug safety and pharmacovigilance field.

At Alkermes, from 2012 to 2013, they served as a Consultant, although there is no additional information available regarding their role at the company.

During their time at Genzyme Corp., Nordeen was a Consultant and held the positions of Program Manager, Technical Architecture Lead, and Business Configuration SME. Ken oversaw the procurement and implementation of a pharmacovigilance system, including AE reporting systems and signal detection and exploratory analysis systems.

At Grunenthal, Nordeen was a Consultant and led a team responsible for upgrading Argus Safety and Argus Insight software.

Ken'srole at Acorda Therapeutics, Inc. as a Consultant involved implementing Oracle Argus Safety and Insight, previously outsourced to a Contract Research Organization (CRO). Ken reviewed and updated system designs, business SOPs, and validation packages.

Nordeen also worked as a Consultant at Infinity Pharmaceuticals, where they were a Subject Matter Expert (SME) responsible for the implementation of a new drug safety reporting system. Ken reviewed and updated validation packages and was involved in business configuration.

Currently, Nordeen is the President and CEO of Covigilant, which provides an expertly managed Argus Safety database environment. The company configures and monitors the database, performs validation, and handles drug safety reporting.

In addition, Nordeen was also a Health Sciences Gold Partner at Oracle in 2012. It is likely that this role involved providing support and expertise in drug safety and pharmacovigilance using Oracle's technology.

Ken Nordeen attended Manchester High School from 1973 to 1976. Ken then pursued a Bachelor of Science degree in Mechanical Engineering at Cornell University from 1976 to 1980.